Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).

Abstract: A compound represented by the formula (Ia) (wherein R1a, R2a, and R3 to R5 are the same as defined in the description), a prodrug thereof, a pharmaceutically acceptable salt thereof, or solvate thereof. The compounds are useful in the prevention of or treatment for diseases relating to NAD(P)H.

Abstract: A head module includes a nozzle sheet, a wiring board, and a module frame having a plurality of head-chip positioning holes formed therein, and a head chip including an electrode. The head chip is disposed in each head-chip positioning hole. The nozzle sheet is disposed on a first surface of the module frame so as to partially cover the head-chip positioning hole. The size of the nozzle sheet is set to a minimum size required for partially covering the head-chip positioning hole. The head chip is disposed from a second surface of the module frame. The electrode is exposed through an area of the head-chip positioning hole not covered by the nozzle sheet. An electrode of the wiring board is electrically connected to the electrode of the head chip and the wiring board is disposed on the first surface of the module frame so as to cover the exposed electrode.

Abstract: A connector has a flat wide housing (20) formed of synthetic resin and a plurality of female terminal fittings (41) are accommodated inside the housing (20). Each terminal fittings (41) includes a barrel (44) fixed to an end of an electric wire (70) and a box-shaped body (43) forward from the barrel (44) and configured for connection with a terminal fitting of a mating connector. A wall of the housing (20) surrounding the terminal fittings (41) is constructed of a thin part (22) forward from a midway position in a longitudinal direction of the housing (20) and of a thick part (23) thicker than the thin part (22) and rearward from the midway position. The body (43) of each of the female terminal fittings (41) is disposed partly in the thin part (22) and partly in the thick part (23).

Abstract: A compound represented by the formula (Ia) (wherein R1a, R2a, and R3 to R5 are the same as defined in the description), a prodrug thereof, a pharmaceutically acceptable salt thereof, or solvate thereof. The compounds are useful in the prevention of or treatment for diseases relating to NAD(P)H.

Abstract: A connector has a flat wide housing (20) formed of synthetic resin and a plurality of female terminal fittings (41) are accommodated inside the housing (20). Each terminal fittings (41) includes a barrel (44) fixed to an end of an electric wire (70) and a box-shaped body (43) forward from the barrel (44) and configured for connection with a terminal fitting of a mating connector. A wall of the housing (20) surrounding the terminal fittings (41) is constructed of a thin part (22) forward from a midway position in a longitudinal direction of the housing (20) and of a thick part (23) thicker than the thin part (22) and rearward from the midway position. The body (43) of each of the female terminal fittings (41) is disposed partly in the thin part (22) and partly in the thick part (23).

Abstract: A connection body (41), of a connector for a towing vehicle, to be connected to a wire harness of a to-be-towed object and a connection body (42) of the connector to be connected to a wire harness of a towing vehicle body are approximately cylindrical. Terminals (32, 33) inside the connection bodies (41, 42) are composed of a common metal piece (31). The connector is connected to a wire harness (35) of the towing vehicle body not by using an exclusive cylindrical connector but by directly connecting a core wire to the terminal (32). To prevent water from penetrating into the connector, an O-ring (38), a sealing medium (57), and a rubber plug (59) are mounted on the connector. A protector (37) is installed on an insertion portion of the wire harness (35) of the towing vehicle body into the housing (30).

Abstract: A connection body (41), of a connector for a towing vehicle, to be connected to a wire harness of a to-be-towed object and a connection body (42) of the connector to be connected to a wire harness of a towing vehicle body are approximately cylindrical. Terminals (32, 33) inside the connection bodies (41, 42) are composed of a common metal piece (31). The connector is connected to a wire harness (35) of the towing vehicle body not by using an exclusive cylindrical connector but by directly connecting a core wire to the terminal (32). To prevent water from penetrating into the connector, an O-ring (38), a sealing medium (57), and a rubber plug (59) are mounted on the connector. A protector (37) is installed on an insertion portion of the wire harness (35) of the towing vehicle body into the housing (30).

Abstract: The present invention provides a compound of the formula (I): wherein R1, R2, R3 and R4 are each independently hydrogen, optionally substituted alkyl, hydroxy, optionally substituted alkoxy or the like, R5 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocyclic or the like, R6 is hydrogen, optionally substituted alkyl or the like, R7 is hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclic or the like, A is S or O and a broken line represents presence or absence of a bond, pharmaceutically acceptable salt or hydrate thereof and a pharmaceutical composition or a pharmaceutical composition for use as an endothelin receptor antagonist, a peripheral circulation insufficiency-improving agent or a macrophage foam cell formation inhibitor comprising the compound.

Abstract: The present invention relates to a composition for treating or preventing brain edemas which comprises containing an endothelin antagonist as an active ingredient, for example, the compound of the following formula (I): ##STR1## or pharmaceutically acceptable salts or hydrates thereof, bosentan, cyclo?D-aspartyl-L-?3-(4-phenylpiperazin-1-ylcarbonyl)!-alanyl-L-aspartyl- D-?2-(2-thienyl)!glycyl-L-leucyl-D-tryptophyl!disodium or cyclo ?D-Asp-L-Pro-D-Val-L-Leu-D-Trp!.Furthermore, the present invention provides a method for treating or preventing brain edemas, which comprises administering an effective amount of an endothelin antagonist and use of an endothelin antagonist for the manufacture of a medicament for treating or preventing brain edemas.An endothelin antagonist exhibits an inhibitory effect, on all brain edemas regardless of the onset mechanism and thus is highly useful in the treatment or prevention of brain edemas.

Abstract: A plug cap freely mountable on or removable from an elongated bore, especially for a spark plug in internal combustion engines or the like. The plug cap is provided with a rain cover, seal, and a pipe-holding portion. The latter has, on its internal face, a circular groove and a plurality of protrusions projecting radially inwardly. These grooves and protrusions, and the deflection thereof on insertion into the bore, give elasticity to the seal and to the pipe-holding portion. When the plug cap is pressed into the bore, there is no curling up of the pipe-holding portion, thereby ensuring a reliable seal. After insertion, the protrusions of the pipe-holding portion, which are formed integrally with the seal, are pressed against the external face of the ignition pipe, so that the latter can be held more reliably.